Search for brain tumor biomarkers in urine strikes gold

By Tom Ulrich

A good biomarker is one whose levels go up or down as a patient’s disease worsens or wanes. A great biomarker also gives key insights into disease development. A really great biomarker does both of these things and also serves as a treatment target.

With a protein called netrin-1, Edward Smith, MD, and Michael Klagsbrun, PhD, seem to have hit the trifecta. In a recent paper in Cancer Research, they report a clear relationship between urine netrin levels and medulloblastoma, the most common malignant brain tumor of children.

And show that netrin fuels the tumor’s invasion into healthy brain tissue.

And that blocking netrin may, at least in the laboratory, check the tumor’s spread.

From brain to bladder

For years, Smith – a brain surgeon and Boston Children’s Hospital’s director of pediatric cerebrovascular surgery – has been searching for ways to use urine to watch for relapses in children with brain tumors.

Vector

The search started when Smith attended a seminar by Marsha Moses, MD, PhD, director of the hospital’s Vascular Biology Program (VBP), who studies urine biomarkers for ovarian and breast cancer. Inspired, he started learning from her how to isolate proteins from urine and assess them as potential biomarkers.

In 2008, the pair showed that a panel of urine biomarkers correlated with the presence of a variety of brain tumors. But just knowing a tumor is there wasn’t enough for Smith. As a surgeon, he wanted to know what the tumor is doing.

“The biggest problem I face as a surgeon is invasion,” he says. “Invasive tumors put fingers out into the surrounding tissue, making them harder to operate on. They’re also harder to treat with chemotherapy and radiation and more prone to metastasis.”

While gene signatures can tell us something about a medulloblastoma’s behavior, reading those signatures requires having tumor tissue on hand. Gene signatures also can’t help track a brain tumor’s response to treatment – at least not without taking additional biopsies – or raise an alarm if a tumor returns. Those are things that are best detected using markers pulled from an easily collected fluid. And urine is probably the easiest, least invasive fluid of all.

Marker hunters

Michael Klagsbrun, PhD
Michael Klagsbrun, PhD

To home in on urine markers that could provide intel on tumor presence and behavior, Smith teamed up with Klagsbrun. For more than 40 years, Klagsbrun has been working in the VBP to tease apart the intricate web of chemical signals influencing blood vessel growth (angiogenesis) and cancer development. He is particularly interested in semaphorins, a family of axon guidance factors that influences nerve growth during development and also seem to play a role in angiogenesis.

Netrin is also an axon guidance factor. During fetal development, netrin and semaphorins work in opposition. Netrin creates a trail of chemical breadcrumbs that young nerve fibers follow as they grow. Semaphorins block or deflect nerve growth.

“There’s a balance between them,” Klagsbrun says, “between pro-growth and anti-growth.” Or, as Smith puts it, “Netrin is like the gas, semaphorins the brakes.”

Looking at cell lines, the pair found that netrin holds a great deal of pro-growth sway over medulloblastomas. Adding netrin to medulloblastoma cell lines caused a jump in tumor cell invasion while also activating a signaling pathway known to be involved in cancer development (thus making netrin a potential therapeutic target.) At the same time, blocking netrin using a variety of techniques (e.g., receptor blockade, siRNA, neutralizing antibodies and small molecules) reduced invasion.

Nimbler tumor screening

Michael Klagsbrun, PhD
Edward Smith, MD

Turning to patient samples, Smith and Klagsbrun found that the tumor cells of one patient produced significantly more netrin than adjacent, normal brain cells. They also found that urine from 16 medulloblastoma patients contained between five and 10 times as much netrin as urine from 12 healthy controls, and that urine netrin levels drop after a patient undergoes surgery.

As a bonus, urine levels alone could single out patients with highly invasive tumors, the ones that had spread more aggressively.

“You can’t always see on an MRI if a child will have an invasive tumor,” Smith notes. “But here we saw a gradient of netrin levels that increased as we looked from healthy controls across to high-risk patients.”

For the moment, Smith envisions cheaper, measurable and more frequent screening of medulloblastoma patients after treatment.

“Measuring urine netrin could help guide decisions about when a patient might need a scan and additional treatment,” he says. “The ‘pie-in-the-sky’ scenario would be to use urine biomarkers like netrin to tailor a patient’s treatment regimen. Because urine proteins change more quickly than scans, we could be more nimble with our treatment approach.”

RSS From Medical Design & Outsourcing

  • Herrmann Ultrasonics, Inc. announces its 25 Year Anniversary
    In 1990, Thomas Herrmann, the son of Walter Herrmann, who founded Herrmann Ultraschalltechnik GmbH in 1961, established Herrmann Ultrasonics Inc. in the Chicago area. Hermann Ultrasonics, Inc. is proud to recognize a milestone year in observance of their 25th anniversary. Herrmann Ultrasonics has been focused on providing ultrasonic welding technology for various markets such as […]
  • Consumer Health Applications receive the most attention today, but the future is elsewhere
    Wearables for health fall into a wide range of technologies, functions, use cases and over-arching regulatory frameworks that developers and prospective entrants have to understand in order to effectively compete. Using an underlying taxonomy for human health, we establish a health-focused wearables taxonomy around three major categories—applications, use cases, and form factors—the three areas critical […]
  • Paralyzed men move legs with new non-invasive spinal cord stimulation
    Five men with complete motor paralysis were able to voluntarily generate step-like movements thanks to a new strategy that non-invasively delivers electrical stimulation to their spinal cords, according to a new study funded in part by the National Institutes of Health. The strategy, called transcutaneous stimulation, delivers electrical current to the spinal cord by way […]
  • SCHURTER’s new power entry module offers IP 54 protection with V-Lock cord sets
    SCHURTER is pleased to announce, that its power entry module, series 5707, now offers IP 54 protection with V-Lock cord sets at the power input, in addition to IP 65 protection to the equipment. The sealed module is ideal for use in medical equipment exposed to leaks, drips and spills, as well as equipment subject […]
  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]
  • Saelig introduces Multiple Instrument System MIS4 universal test system
    Saelig Company has introduced the ABI Electronics’ Multiple Instrument Station MIS4, an all-in-one testing tool that provides all commonly required test instruments in one compact programmable hardware module, mounted in a compact case or installed in a PC-drive bay. Controlled by ABI’s sophisticated SYSTEM 8 Ultimate PC software with a simple yet programmable operator interface, […]
  • AssurX announces document management software update for small to mid-size companies in FDA regulated industries
    AssurX, an enterprise quality management, risk and regulatory compliance solution provider, announces the release of the latest update to their AssurX document management software. The document management solution provides a cost-effective solution for small to medium sized companies faced with streamlined operations and is fully compliant for FDA regulated industries. Ideal solution for small to […]
  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]

Leave a Reply